Targeted inhibition of amyloidogenesis using a non-toxic, serum stable strategically designed cyclic peptide with therapeutic implications.


Journal

Biochimica et biophysica acta. Proteins and proteomics
ISSN: 1878-1454
Titre abrégé: Biochim Biophys Acta Proteins Proteom
Pays: Netherlands
ID NLM: 101731734

Informations de publication

Date de publication:
05 2020
Historique:
received: 01 10 2019
revised: 24 01 2020
accepted: 31 01 2020
pubmed: 8 2 2020
medline: 18 7 2020
entrez: 8 2 2020
Statut: ppublish

Résumé

Amyloidogenic disorders are currently rising as a global health issue, prompting more and more studies dedicated to the development of effective targeted therapeutics. The innate affinity of these amyloidogenic proteins towards the biomembranes adds further complexities to the systems. Our previous studies have shown that biologically active peptides can effectively target amyloidogenesis serving as an efficient therapeutic alternative in several amyloidogenic disorders. The structural uniqueness of the PWWP motif in the de novo designed heptapeptide, KR7 (KPWWPRR-NH

Identifiants

pubmed: 32032759
pii: S1570-9639(20)30019-4
doi: 10.1016/j.bbapap.2020.140378
pii:
doi:

Substances chimiques

Amyloid 0
Insulin 0
Peptides, Cyclic 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

140378

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Ranit Pariary (R)

Department of Biophysics, Bose Institute, P-1/12 CIT Scheme VII (M), Kolkata, 700054, India.

Baijayanti Ghosh (B)

Department of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII (M), Kolkata, 700054, India.

Zuzana Bednarikova (Z)

Department of Biophysics, Institute of Experimental Physics, Slovak Academy of Sciences, Kosice, Slovakia.

Kyriakos Gabriel Varnava (KG)

School of Chemical Sciences, The University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Bhisma N Ratha (BN)

Department of Biophysics, Bose Institute, P-1/12 CIT Scheme VII (M), Kolkata, 700054, India.

Sreyan Raha (S)

Department of Physics, Bose Institute, 93/1 APC Road, Kolkata 700009, India.

Dipita Bhattacharyya (D)

Department of Biophysics, Bose Institute, P-1/12 CIT Scheme VII (M), Kolkata, 700054, India.

Zuzana Gazova (Z)

Department of Biophysics, Institute of Experimental Physics, Slovak Academy of Sciences, Kosice, Slovakia.

Vijayalekshmi Sarojini (V)

School of Chemical Sciences, The University of Auckland, Private Bag, 92019, Auckland, New Zealand.

Atin K Mandal (AK)

Department of Molecular Medicine, Bose Institute, P-1/12 CIT Scheme VII (M), Kolkata, 700054, India.

Anirban Bhunia (A)

Department of Biophysics, Bose Institute, P-1/12 CIT Scheme VII (M), Kolkata, 700054, India. Electronic address: bhunia@jcbose.ac.in.

Articles similaires

alpha-Synuclein Humans Animals Mice Lewy Body Disease

Amyloid accelerator polyphosphate fits as the mystery density in α-synuclein fibrils.

Philipp Huettemann, Pavithra Mahadevan, Justine Lempart et al.
1.00
Polyphosphates alpha-Synuclein Humans Amyloid Molecular Dynamics Simulation
Humans Insulin Resistance Muscle, Skeletal Oxidative Stress Oxidation-Reduction
Streptomyces Biofilms Anti-Bacterial Agents Peptides, Cyclic Microbial Sensitivity Tests

Classifications MeSH